ATI RN
ATI Pharmacology Proctored
1. A healthcare provider is assessing a client who is taking levothyroxine. The healthcare provider should recognize that which of the following findings is a manifestation of levothyroxine overdose?
- A. Insomnia
- B. Constipation
- C. Drowsiness
- D. Hypoactive deep-tendon reflexes
Correct answer: A
Rationale: Insomnia is a common symptom of levothyroxine overdose due to excessive stimulation of the central nervous system. Levothyroxine is a thyroid hormone replacement medication, and an overdose can lead to hyperthyroidism symptoms, including insomnia. Constipation and drowsiness are not typically associated with levothyroxine overdose. Hypoactive deep-tendon reflexes are more indicative of hypothyroidism rather than an overdose of levothyroxine.
2. A client is to receive Pamidronate for bone pain related to cancer. What precaution should the nurse take during the administration of Pamidronate?
- A. Inspect the skin for redness and irritation around the injection site.
- B. Assess the IV site for thrombophlebitis frequently during administration.
- C. Instruct the client to lie down for 30 minutes after oral administration.
- D. Monitor for signs of anaphylaxis for 20 minutes after intramuscular injection.
Correct answer: B
Rationale: Pamidronate is typically administered through IV infusion, which can cause irritation to veins. The nurse should frequently assess the IV site for thrombophlebitis during the administration to promptly detect any potential complications related to the infusion. Inspecting the skin for redness and irritation around the injection site (Choice A) is not directly related to IV infusion. Instructing the client to lie down after oral administration (Choice C) is not necessary for IV administration. Monitoring for signs of anaphylaxis after an intramuscular injection (Choice D) is not relevant for an IV infusion of Pamidronate.
3. A healthcare professional is caring for a hospitalized client who has an activated partial thromboplastin time (aPTT) greater than 1.5 times the expected reference range. Which of the following blood products should the healthcare professional prepare to transfuse?
- A. Whole blood
- B. Platelets
- C. Fresh frozen plasma
- D. Packed red blood cells
Correct answer: C
Rationale: Fresh frozen plasma is the correct choice for a client with an elevated aPTT because it contains essential coagulation factors that can help correct coagulopathy and prevent bleeding. It is rich in clotting factors like fibrinogen, factors V and VIII, which are crucial in maintaining proper blood clotting function. Whole blood (Choice A) is not typically used to correct coagulopathy and is more suitable for situations requiring both volume and oxygen-carrying capacity. Platelets (Choice B) are indicated for thrombocytopenia, not for correcting coagulation factors. Packed red blood cells (Choice D) are used to increase oxygen-carrying capacity in cases of anemia, not for correcting coagulopathy.
4. A client is starting a new prescription for furosemide. Which of the following instructions should the nurse include?
- A. Weigh yourself daily.
- B. Limit sodium intake.
- C. Increase potassium intake.
- D. Avoid potassium-rich foods.
Correct answer: A
Rationale: The correct instruction to include when starting furosemide is to weigh yourself daily. Daily weighing helps monitor for fluid loss or retention, which is crucial when taking a diuretic like furosemide. Choices B, C, and D are incorrect because although monitoring sodium intake and potassium levels are important when taking furosemide, the most immediate and direct way to assess the medication's effectiveness and the body's response is through daily weight monitoring.
5. A client with Hodgkin's disease is receiving Cyclophosphamide IV. Which medication should be administered concurrently to prevent an adverse effect of Cyclophosphamide?
- A. Uroprotectant agent, such as mesna
- B. Opioid, such as morphine
- C. Loop diuretic, such as furosemide
- D. H1 receptor antagonist, such as diphenhydramine
Correct answer: A
Rationale: Mesna, an uroprotectant agent, is administered with nitrogen mustard chemotherapy drugs like Cyclophosphamide to prevent hemorrhagic cystitis, a common adverse effect. Mesna works by binding to and inactivating the toxic metabolites of Cyclophosphamide in the bladder, thereby reducing the risk of bladder toxicity.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access